Heska Corp. (HSKA) Downgraded to “Neutral” at Sidoti
HSKA has been the topic of several other reports. Zacks Investment Research lowered shares of Heska Corp. from a buy rating to a hold rating in a research report on Thursday, October 20th. Gabelli lowered shares of Heska Corp. from a buy rating to a hold rating in a research report on Thursday, August 4th. Finally, B. Riley restated a neutral rating and issued a $53.00 price target on shares of Heska Corp. in a research report on Wednesday, November 2nd. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of Buy and an average target price of $55.83.
Shares of Heska Corp. (NASDAQ:HSKA) traded up 1.59% during midday trading on Tuesday, hitting $65.78. 20,518 shares of the company’s stock traded hands. The company has a 50 day moving average price of $57.07 and a 200 day moving average price of $47.78. The firm has a market capitalization of $453.75 million, a price-to-earnings ratio of 52.67 and a beta of 0.74. Heska Corp. has a 1-year low of $26.25 and a 1-year high of $69.80.
Heska Corp. (NASDAQ:HSKA) last announced its earnings results on Tuesday, November 1st. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.25 by $0.20. The firm had revenue of $33.40 million for the quarter, compared to the consensus estimate of $31.36 million. Heska Corp. had a net margin of 7.55% and a return on equity of 10.46%. The company’s revenue for the quarter was up 19.3% compared to the same quarter last year. Equities analysts anticipate that Heska Corp. will post $1.32 earnings per share for the current year.
In related news, CFO Jason A. Napolitano sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, September 1st. The shares were sold at an average price of $52.53, for a total transaction of $262,650.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kevin S. Wilson sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, August 29th. The stock was sold at an average price of $51.80, for a total transaction of $1,036,000.00. Following the sale, the chief executive officer now directly owns 110,000 shares of the company’s stock, valued at $5,698,000. The disclosure for this sale can be found here. 15.30% of the stock is currently owned by company insiders.
Several large investors have recently bought and sold shares of the company. Prudential Financial Inc. increased its stake in Heska Corp. by 229.6% in the first quarter. Prudential Financial Inc. now owns 22,250 shares of the company’s stock worth $634,000 after buying an additional 15,500 shares during the period. Acadian Asset Management LLC increased its stake in Heska Corp. by 21.5% in the second quarter. Acadian Asset Management LLC now owns 102,804 shares of the company’s stock worth $3,821,000 after buying an additional 18,211 shares during the period. Adams Diversified Equity Fund Inc. acquired a new stake in Heska Corp. during the second quarter worth $279,000. Pembroke Management LTD acquired a new stake in Heska Corp. during the second quarter worth $5,096,000. Finally, Bank of Montreal Can acquired a new stake in Heska Corp. during the second quarter worth $128,000. 71.80% of the stock is owned by institutional investors and hedge funds.
About Heska Corp.
Heska Corporation develops, manufactures, markets, sells and supports veterinary products. The Company focuses on the canine and feline companion animal health markets. Its segments include Core Companion Animal Health segment, which includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, and single use products and services, such as heartworm diagnostic tests, heartworm preventive products, allergy immunotherapy products and allergy testing, and Other Vaccines, Pharmaceuticals and Products segment, which includes private label vaccine and pharmaceutical production, primarily for cattle but also for other animals, including small mammals.
Receive News & Stock Ratings for Heska Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corp. and related stocks with our FREE daily email newsletter.